Polylactide-co-glycolide nanoparticles of antitubercular drugs: Formulation, characterization and biodistribution studies

Therapeutic Delivery

Volumn 5, Issue 12, 2014, Pages 1247-1259

  Chawla, Ruchi ^a   Solanki, Harshendra S ^a   Kheruka, Subhash Chand ^b   Gambhir, Sanjay ^b   Dube, Veeresh ^b   Aggarwal, Lalit M ^c   Mishra, Brahmeshwar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^c BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; NANOPARTICLE; POLYGLACTIN; POLYLACTIDE CO GLYCOLIDE NANOPARTICLE; TECHNETIUM 99M; UNCLASSIFIED DRUG; DRUG CARRIER; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; EMULSION; EVAPORATION; EX VIVO STUDY; GAMMA SCINTIGRAPHY; IN VIVO STUDY; INTERNALIZATION; LIVER; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; MONONUCLEAR PHAGOCYTE; NONHUMAN; RADIOACTIVITY; RAT; SPLEEN; ANIMAL; CHEMISTRY; CONFOCAL MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PHARMACEUTICS; SCINTISCANNING; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; HUMANS; MACROPHAGES, ALVEOLAR; MALE; MICROSCOPY, CONFOCAL; NANOPARTICLES; PARTICLE SIZE; POLYGLACTIN 910; RADIONUCLIDE IMAGING; RATS; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 84919787508     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.88     Document Type: Article

References (42)

1. World Health Organization. Global tuberculosis report 2011. 71-81 (2011) www.who.int/tb/publications/global-report/2011/gtbr11-full.pdf
2. World Health Organization. Global tuberculosis report 2012. (2012) www.who.int/tb/publications/global-report/gtbr12-main.pdf
3. Riley R. Transmission and environmental control of tuberculosis. In: Tuberculosis. Reichman L, Hershfield E (Eds). Marcel Deckker, NY, USA, 16-35 (1993).
4. Wolf AJ, Linas B, Trevejo-Nunez GJ et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J. Immunol. 179(4), 2509-2519 (2007).
5. Tiwari S, Chaturvedi AP, Tripathi YB et al. Macrophagespecific targeting of isoniazid through mannosylated gelatin microspheres. AAPS PharmSciTech. 12(3), 900-908 (2011).
6. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001).
7. Wijagkanalan W, Kawakami S, Takenaga M et al. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J. Control. Release 125(2), 121-130 (2008).
8. Krishnan N, Robertson BD, Thwaites G. The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis. Tuberculosis 90(6), 361-366 (2010).
9. Poznansky M, Juliano RL. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev. 36(4), 277-336 (1984).
10. Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28(35), 5344-5357 (2007).
11. Pillai G, Fourie PB, Padayatchi N et al. Recent bioequivalence studies on fixed dose combination antituberculosis drug formulations available on the global market. Int. J. Tuberc. Lung Dis. 3(11), S309-S316 (1999).
12. Wilczewska AZ., Niemirowicz K. Markiewicz KH et al. Nanoparticles as drug delivery systems. Pharmacol. Rep. 64(5), 1020-1037 (2012).
13. Pandey R, Sharma A, Zahoor A et al. Poly (DL-lactideco-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52(6), 981-986 (2003).
14. Pandey R, Zahoor A, Sharma S et al. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 83(6), 373-378 (2003).
15. Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv. 13(4), 287-294 (2006).
16. du Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy: Current drug delivery approaches. Respiratory Res. 7, 118 (2006).
17. Wilding IR, Coupe AJ, Davis SS. The role of g-scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. 46 (1-3), 103-124 (2001).
18. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56(9), 1257-1272 (2004).
19. Haruta S, Kawai K, Jinnouchi S et al. Evaluation of absorption kinetics of orally administered theophylline in rats based on gastrointestinal transit monitoring by gamma scintigraphy. J. Pharm. Sci. 90(4), 464-473 (2001).
20. 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT. EJNMMI Res. 3(1), 60 (2013)
21. Zambauxa MF, Bonneauxa F, Grefb R et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release 50(1-3), 31-40 (1998).
22. Zili Z, Sfar S, Fessi H. Preparation and characterization of poly-epsiloncaprolactone nanoparticles containing griseofulvin. Int. J. Pharm. 294(1-2), 261-267 (2005).
23. Muthu MS, Rawat MK, Mishra A et al. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine 5(3), 323-333 (2005).
24. Rawat MK, Jain A, Mishra A et al. Effect of lipid matrix on characteristics of repaglinide loaded solid lipid nanoparticles for oral delivery. Therap. Deliv. 1(1), 63-73 (2010).
25. Mira EG, Egea MA, Souto EB et al. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 22(4), 045101 (2011).
26. Reddy LH, Murthy RS. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS PharmSciTech. 6 (2), 158-166 (2005).
27. Chawla R, Jaiswal S, Mishra B. Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design. Expert Opin. Drug Deliv. 11(1), 31-43 (2014).
28. Liang WW, Shi X, Deshpande D et al. Oligonucleotide targeting to alveolar macrophages by mannose receptormediated endocytosis. Biochim. Biophys. Acta. 1279 (2), 227-234 (1996).
29. Zhou H, Zhang Y, Biggs DL et al. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J. Control. Release 107(2), 288-299 (2005).
30. Halder KK, Mandal B, Debnath MC et al. Chloramphenicol-incorporated poly lactide-co-glycolide (PLGA) nanoparticles: Formulation, characterization, technetium-99m labeling and biodistribution studies. J. Drug Target. 16(4), 311-320 (2008).
31. Wu XS, Wang N. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation. J. Biomater. Sci. 12(1), 21-34 (2001)
32. Vert M, Mauduit J, Li S. Biodegradation of PLA/GA polymers: Increasing complexity. Biomaterials 15(15), 1209-1213 (1994).
33. Heller J, Barr J, NG SY et al. Poly(ortho esters): synthesis, characterization, properties and uses. Adv. Drug Deliv. Rev. 54(7), 1015-1039 (2002).
34. Hest RV, Baars H, Kik S et al. Hepatotoxicity of rifampinpyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin. Infect. Dis. 39(4), 488-496 (2004).
35. Moghimi SM, Hawley AE, Christy NM et al. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett. 344(1), 25-30 (1994).
36. Garcia-Garcia E, Andrieux K, Gil S et al. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298 (2), 274-292 (2005).
37. de Faria TJ, Romana M, de Souzaa NM et al. An isoniazid analogue promotes mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages. Antimicrob. Agents Chemother. 56(5), 2259-2267 (2012).
38. Clemens DL, Lee BY, Xue M et al. Targeted intracellular delivery of antituberculosis drugs to mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob. Agents Chemother. 56(5), 2535-2545 (2012).
39. Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 26(11), 2401-2416 (2009)
40. Sasmono RT, Oceandy D, Pollard JW et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 101(3), 1155-1163 (2003).
41. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2(1), 108-119 (2005).
42. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release nbvcdfgvbngvfcxzsdfgrjhyytfredwqa GTR4EQWA 8 161 (2), 264-273 (2012).